⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,734.19
−1.44%
FTSE ADX
9,588.41
−1.17%
TASI
9,695.86
−2.32%
QE Index
8,611.10
−0.37%
S&P 500
7,649.47
−0.18%
Nasdaq 100
29,087.33
+0.44%
Nifty 50
22,600.00
−0.39%
Sensex
73,123.83
−0.17%
KSE-100
162,374.88
−0.95%
DFM:EMIRATESNBD
AED 30.00
−3.47%
ADX:IHC
AED 350.00
−0.57%
SAU:2222
SAR 25.40
−0.70%
DSMD:QNBK
QAR 15.50
−1.02%
NAS:NVDA
$212.91
+0.33%
NYSE:TSM
$419.42
+1.71%
NSE:RELIANCE
₹1,190.00
+0.46%
KAR:OGDC
Rs 298.12
−0.79%
Gold
$3,999.39
−0.62%
Brent
$116.10
+2.84%
BTC
$81,614.22
+0.37%
ETH
$2,402.62
+0.69%
DFM General
5,734.19
−1.44%
FTSE ADX
9,588.41
−1.17%
TASI
9,695.86
−2.32%
QE Index
8,611.10
−0.37%
S&P 500
7,649.47
−0.18%
Nasdaq 100
29,087.33
+0.44%
Nifty 50
22,600.00
−0.39%
Sensex
73,123.83
−0.17%
KSE-100
162,374.88
−0.95%
DFM:EMIRATESNBD
AED 30.00
−3.47%
ADX:IHC
AED 350.00
−0.57%
SAU:2222
SAR 25.40
−0.70%
DSMD:QNBK
QAR 15.50
−1.02%
NAS:NVDA
$212.91
+0.33%
NYSE:TSM
$419.42
+1.71%
NSE:RELIANCE
₹1,190.00
+0.46%
KAR:OGDC
Rs 298.12
−0.79%
Gold
$3,999.39
−0.62%
Brent
$116.10
+2.84%
BTC
$81,614.22
+0.37%
ETH
$2,402.62
+0.69%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Open
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› NKTR
N
Nektar Therapeutics
NAS:NKTR
Healthcare
CBOEFTSE:MRUT
NASDAQ:NCX
$37.13
−3.93%
Live
In session · ≈
AED 136.36
· Market cap
$1.27B
· Next earnings
Thu 5 Nov
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Nektar Therapeutics · News · TradingHolo
NKTR news
Headlines tagged to this company
SE
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
Seeking Alpha · 11 d ago
DO
Nektar Therapeutics Initiated at Neutral by UBS
Dow Jones Newswires · 11 d ago
DO
Nektar Therapeutics Price Target Announced at $130.00/Share by Leerink Partners
Dow Jones Newswires · 11 d ago
DO
Nektar Therapeutics Price Target Maintained With a $178.00/Share by BTIG
Dow Jones Newswires · 14 d ago
TR
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
TradingView · 14 d ago
DO
Nektar Therapeutics Initiated at Market Perform by Raymond James
Dow Jones Newswires · 14 d ago
DO
Nektar Therapeutics Price Target Maintained With a $185.00/Share by HC Wainwright & Co.
Dow Jones Newswires · 21 d ago
TR
HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target
TradingView · 21 d ago
ST
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
Stocktwits · 22 d ago
SE
Nektar drops after new mid-stage trial data for hair loss drug
Seeking Alpha · 22 d ago
DO
Nektar Stock Sinks Despite Promising Hair Loss Treatment Data — Barrons.com
Dow Jones Newswires · 22 d ago
QU
NKTR: REZPEG showed durable hair regrowth and strong safety in alopecia areata, with lasting off-drug effects
Quartr · 22 d ago
QU
NKTR: REZPEG showed durable hair regrowth and broad immune modulation, supporting its first-line potential
Quartr · 22 d ago
TR
Nektar presents durable Phase 2b rezpegaldesleukin data; Phase 3 ZENITH AA starts early 2027
TradingView · 22 d ago
QU
NKTR: Rezpegaldesleukin shows durable, deepening efficacy and safety in alopecia areata and atopic dermatitis
Quartr · 22 d ago
RE
Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
Reuters · 22 d ago
QU
NKTR: REZPEG rapidly improved clinical and molecular outcomes in moderate-to-severe atopic dermatitis
Quartr · 22 d ago
TR
Weekly Recap: Phase 3 ZENITH AD trials and $90M jury award
TradingView · 25 d ago
More news →